Insulet delivered robust third-quarter results, with revenue reaching $706.3 million, a 29.9% increase year-over-year, driven by strong Omnipod product growth. The company exceeded its revenue guidance and raised its full-year revenue and margin guidance, reflecting the strong performance of its Omnipod 5 system.
Revenue for Q3 2025 was $706.3 million, a 29.9% increase from the prior year, surpassing the company's guidance.
Total Omnipod revenue grew by 31.0% to $699.2 million, with significant growth in both U.S. and International markets.
Gross margin improved to 72.2%, up 290 basis points over the prior year, indicating enhanced profitability.
Diluted EPS was $1.24, consistent with adjusted diluted EPS, demonstrating solid earnings performance.
Insulet raised its full-year 2025 revenue and margin guidance, anticipating continued strong growth for Omnipod products and improved profitability.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance